Article
Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival.
JCO precision oncology - 1 Jan 2023
De Brian, Farooqi Ahsan S, Mitchell Kyle G, Ludmir Ethan B, Lewis Jeff, Rinsurongkawong Waree, Rinsurongkawong Vadeerat, Lee J Jack, Swisher Stephen G, Gibbons Don L, Zhang Jianjun, Le Xiuning, Elamin Yasir Y, Gomez Daniel R, Ning Matthew S, Lin Steven H, Liao Zhongxing, Chang Joe Y, Vaporciyan Ara A, Heymach John V, Antonoff Mara B, Gandhi Saumil J
Abstract excerpt
PURPOSE: Local consolidative therapy (LCT) for patients with synchronous oligometastatic non-small-cell lung cancer is an evolving treatment strategy, but outcomes following LCT stratified by genetic mutations have not been reported. We sought to identify genomic associations with overall survival (OS) and progression-free survival (PFS) for these patients. METHODS: We identified all patients presenting between...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.